Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Production / Operations Routine +

Optimi Health Launches Standardized Microdose Psilocybin Products for Clinical Research

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

By The Northwire Desk — AI Analysis Jun 16, 2026 · 08:30 OPTI · 6.89 Optimi Health Corp.
Executive Summary
  • Optimi Health completed production of 1 mg and 2 mg microdose psilocybin finished drug products.
  • The new formats are specifically formulated for authorized clinical research organizations to support controlled studies.
  • The release expands the company's psilocybin portfolio beyond the existing 5 mg capsule currently prescribed in Australia for treatment-resistant depression.
  • All products are manufactured in-house at the company's GMP-compliant facility in Princeton, British Columbia, under its Health Canada Drug Establishment License.
  • The company emphasizes validated, consistent dosing compared to traditional dried mushroom microdosing, targeting the accuracy required for clinical research.
Material Impact
  • The announcement is an operational milestone rather than a commercial or financial inflection point.
  • No revenue, pricing, contract values, or partnership details are disclosed.
  • The update directly follows a sequence of similar operational executions: UK Phase 2 trial export (June 10), ibogaine development launch (June 8), and Australian commercial production completion (June 2).
  • The news confirms ongoing platform development and portfolio expansion but does not alter the company's near-term financial trajectory or valuation.
  • Market impact is likely muted, as the announcement aligns with previously communicated strategic goals and does not introduce unexpected catalysts.
OPTI · Price
Company Overview
  • Optimi Health Corp. is a vertically integrated, Health Canada-licensed GMP manufacturer specializing in controlled psychedelic substances, primarily psilocybin and MDMA.
  • The company operates two 10,000 sq ft facilities in Princeton, British Columbia, capable of biomass cultivation, API extraction, encapsulation, and packaging.
  • Commercial presence: Supplies psilocybin (5 mg) for treatment-resistant depression and MDMA (40 mg/60 mg) for PTSD in Australia under the Authorized Prescriber Scheme.
  • Clinical supply: Exports to research institutions globally, including a recent UK Phase 2 trial shipment and upcoming microdose formats for clinical studies.
  • Strategic expansion: Launching an ibogaine initiative in response to U.S. regulatory shifts, aiming to leverage its Canadian GMP infrastructure for emerging psychedelic therapies.
Read the original news release →

More from Optimi Health Corp.

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory Jun 02, 2026 · 07:30

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Production / Operations May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory May 26, 2026 · 07:01

Optimi Health Manufacturing Milestone Validates Capital Raise But Nasdaq Uplifting Remains Primary Valuation Driver

Production / Operations